Inhibition of peroxisome proliferator-activated receptor γ increases estrogen receptor-dependent tumor specification

Cancer Research

Volumn 69, Issue 2, 2009, Pages 687-694

  Yin, Yuzhi ^a   Yuan, Hongyan ^a   Zeng, Xiao ^a,c   Kopelovich, Levy ^b   Glazer, Robert I ^a,d  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SuperArray Bioscience Corporation   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 7,12 DIMETHYLBENZ[A]ANTHRACENE; BETA1 INTEGRIN; CD24 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DNA RESPONSIVE ELEMENT; ENZYME ACTIVATION; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TRANSCRIPTION REGULATION; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BETA CATENIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; ONCOGENE PROTEIN V-AKT; PPAR GAMMA; PREGNANCY; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STEM CELLS; UP-REGULATION;

EID: 58349086542     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2446     Document Type: Article

References (62)

1. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244-51.
2. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61.
3. Lehrke M, Lazar MA. The many faces of PPARγ. Cell 2005;123:993-9.
4. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as chemopreventive agents. Mol Cancer Ther 2002;1:357-63.
5. Stoll BA. Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Eur J Cancer Prev 2002;11:319-25.
6. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4.
7. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000;92:418-23.
8. Yin Y, Bai R, Russell RG, et al. Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. Mol Carcinog 2005;44:42-50.
9. Pighetti GM, Novosad W, Nicholson C, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 2001;21:825-9.
10. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
11. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 2001;11:764-8.
12. Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor γ in the MCF-7 breast cancer cell line. Oncogene 2003;22:5446-50.
13. Nicol CJ, Yoon M, Ward JM, et al. PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004;25:1747-55.
14. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 2000;289:1357-60.
15. Yin Y, Kristipati ST, Yuan H, Kopelovich L, Glazer RI. Modulation of stem cell antigen (Sca-1) expression by the PDK1 and Stat pathways. Proceedings of the American Association for Cancer Research, April 1-4, 2006, Washington, District of Columbia.
16. Foukakis T, Au AY, Wallin G, et al. The Ras effector NORE1Ais suppressed in follicular thyroid carcinomas with a PAX8-PPARγ fusion. J Clin Endocrinol Metab 2006;91:1143-9.
17. Gregory Powell J, Wang X, Allard BL, et al. The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 2004;23:3634-41.
18. Yin Y, Yuan H, Wang C, et al. 3-Phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-γ and promotes adipocyte differentiation. Mol Endocrinol 2006;20:268-78.
19. Glazer RI, Yuan H, Xie Z, Yin Y. PPARγ and PPARγ as modulators of neoplasia and cell fate. PPAR Res 2008;2008:247379.
20. Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 2002;21:198-206.
21. Yin Y, Russell RG, Dettin LE, et al. Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005;65:3950-7.
22. Zeng X, Xu H, Park B-K, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Cα. Cancer Res 2002;62:3538-43.
23. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995;92:39-47.
24. Agostini M, Schoenmakers E, Mitchell C, et al. Non-DNA-bindin γ, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 2006;4:303-11.
25. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP. Modulation of estrogen receptor-α transcriptional activity by the coactivator PGC-1. J Biol Chem 2000;275:16302-8.
26. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A. The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor α (ERRα). J Biol Chem 2003;278:9013-8.
27. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-39.
28. Tozlu S, Girault I, Vacher S, et al. Identification of novel genes that co-cluster with estrogen receptor α in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006;13:1109-20.
29. Buono KD, Robinson GW, Martin C, et al. The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol 2006;293:565-80.
30. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007;176:19-26.
31. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006;439:84-8.
32. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2006;8:R7.
33. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor γ (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002;277:17830-5.
34. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell 2004;3:379-89.
35. Takada I, Suzawa M, Matsumoto K, Kato S. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci 2007;1116:182-95.
36. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 2003;100:15853-8.
37. Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A 2004;101:4158-63.
38. Sotgia F, Williams TM, Cohen AW, Minetti C, Pestell RG, Lisanti MP. Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/β-catenin signaling. Cell Cycle 2005;4:1808-16.
39. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci U S A 2002;99:13771-6.
40. Sharma C, Pradeep A, Wong L, Rana A, Rana B. Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 2004;279:35583-94.
41. Liu J, Wang H, Zuo Y, Farmer SR. Functional interaction between peroxisome proliferator-activated receptor γ and β-catenin. Mol Cell Biol 2006;26:5827-37.
42. Xie Z, Zeng X, Waldman T, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates β-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 2003;63:5370-5.
43. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 2006;103:1480-5.
44. Takahashi K, Murakami M, Yamanaka S. Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem Soc Trans 2005;33:1522-5.
45. Watanabe S, Umehara H, Murayama K, Okabe M, Kimura T, Nakano T. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 2006;25:2697-707.
46. Amundadottir LT, Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998;16:737-46.
47. Denley A, Kang S, Karst U, Vogt PK. Oncogenic signaling of class I PI3K isoforms. Oncogene 2008;27:2561-74.
48. King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 1997;17:4406-18.
49. Kim D, Rath O, KolchW, Cho KH. Ahidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene 2007;26:4571-9.
50. Moshnikova A, Frye J, Shay JW, Minna JD, Khokhlatchev AV. The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. J Biol Chem 2006;281:8143-52.
51. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F, Brossart P. PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways. Blood 2005;106:3888-94.
52. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997;272:5128-32.
53. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996;274:2100-3.
54. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA. Interdomain communication regulating ligand binding by PPAR-γ. Nature 1998;396:377-80.
55. Floyd ZE, Stephens JM. Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes. J Biol Chem 2002;277:4062-8.
56. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 2003;63:958-64.
57. Gunin AG, Bitter AD, Demakov AB, Vasilieva EN, Suslonova NV. Effects of peroxisome proliferator activated receptors-α and -β agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol 2004;182:229-39.
58. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 1995;9:794-804.
59. Liu Y, Gao H, Marstrand TT, et al. The genome landscape of ERα- and ERβ-binding DNA regions. Proc Natl Acad Sci U S A 2008;105:2604-9.
60. Bonofiglio D, Gabriele S, Aquila S, et al. Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells. Clin Cancer Res 2005;11:6139-47.
61. Ferretti E, Arturi F, Mattei T, et al. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines. Endocrinology 2005;146:4009-15.
62. Sarfstein R, Maor S, Reizner N, Abramovitch S, Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 2006;252:241-6.